98%
921
2 minutes
20
Maternal vaccination, or vaccination in pregnancy, offers a critical opportunity to provide protection to pregnant women and simultaneously confer passive immunity to infants in the first months of life, when infections are particularly serious and their immune systems are still developing. Respiratory syncytial virus (RSV) is one such serious infectious disease for newborns, but a newly approved and recommended vaccine for respiratory syncytial virus has been designed to be given to pregnant women to protect their newborns from severe RSV disease when they are most vulnerable. While maternal vaccination has been used for tetanus, pertussis, influenza, COVID-19, and other diseases, vaccination in pregnancy can present unique challenges related to hesitancy and delivery, particularly in lower-resourced settings. Using data from a cross-sectional survey of 400 pregnant and lactating women in Nakuru and Mombasa Counties in Kenya, we examined perspectives related to maternal vaccination and RSV. We conducted a latent class analysis on 12 dichotomized knowledge, attitude, and belief items and then examined factors associated with class membership using a binary logistic regression. We identified two distinct archetypes among study subjects, maternal vaccine "questioners" and maternal vaccine "acceptors." There was a notable difference in perceived vaccination-enabling social norms between "questioners" and "acceptors," and participants using private health facilities were more likely to be in the "questioner" class compared to those using public facilities (aOR: 2.99, 95% CI: 1.32-6.77). This respondent-driven approach to identify groups that may require different communication strategies can help to shape efforts to target preparations for future RSV vaccine introduction in Kenya. Recognizing that "questioners" accounted for nearly one in four participants, these learnings can help to inform tailored health promotion strategies to support informed, confident maternal vaccination decision-making among providers, communities, and pregnant women and mitigate vaccination hesitancy and refusal.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12393705 | PMC |
http://dx.doi.org/10.1371/journal.pgph.0004505 | DOI Listing |
J Med Virol
September 2025
Department of Gynaecology, Shandong Provincial Third Hospital, Shandong University, Jinan, Shandong, China.
Persistent high-risk human papillomavirus (HPV) infection is a leading cause of cervical cancer worldwide. While prophylactic vaccines exist, many women remain at risk due to prior exposure or limited access to vaccination. Current treatments focus on ablating visible lesions but often fail to clear the virus completely.
View Article and Find Full Text PDFInfluenza Other Respir Viruses
September 2025
Oslo Economics, Oslo, Norway.
Background: Respiratory syncytial virus (RSV) is recognized as the primary cause of hospitalizations among children with lower respiratory tract infections in developed countries, placing a significant burden on both patients and healthcare systems. The efficacy, safety, and immunogenicity of maternal vaccination with the novel RSVpreF vaccine have been evaluated in a Phase III clinical trial, showing a decreased risk of severe infection in infants. Our study assesses the cost-effectiveness of the RSVpreF vaccine and seasonal variation of costs in a Norwegian setting.
View Article and Find Full Text PDFJ Public Health (Oxf)
September 2025
Alte University, International School of Medicine, 2 University St, Tbilisi, Georgia, 0177.
Background: Parental vaccine hesitancy (VH) remains a public health concern in Georgia, where misinformation and distrust continue to hinder routine childhood immunization. VH is shaped by psychological, sociocultural, and informational factors, including trust in science, public authorities, and religious institutions. This study examined whether trust-related variables were stronger predictors of VH than traditional sociodemographic characteristics.
View Article and Find Full Text PDFAllergy
September 2025
National Research Center, Institute of Immunology FMBA of Russia, Moscow, Russian Federation.
PLoS One
September 2025
Maternal, Child and Nutrition Department, Bolosso Bombe District Health Office, Bombe, Ethiopia.
Background: Human papillomavirus (HPV) vaccination is a well-established global strategy for the prevention of cervical cancer. However, the uptake of the vaccine varies across regions and countries due to several factors. Although girls are at risk for cervical cancer, there are limited studies measuring vaccination uptake among female adolescents in the study area.
View Article and Find Full Text PDF